hmaxi-k
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00495053)
Timeline
Indications
Mechanism of action
- Calcium-activated potassium channel alpha/beta 1Supplementation
Calcium-activated potassium channel alpha/beta 1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hmaxi-k
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02713789 | Phase 2 | Apr 1, 2015 | Dasman Diabetes Institute, Ion Channel Innovations |
| NCT01870037 | Phase 1 | Jan 1, 2013 | Ion Channel Innovations |
| NCT00495053 | Phase 1 | Apr 1, 2007 | Ion Channel Innovations |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ion Channel Innovations | For profit | 3 | 3 | 2 | 2007 |
| Dasman Diabetes Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1